A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced High-Grade Epithelial Ovarian
Primary Peritoneal
Fallopian Tube Cancers
High Folate Receptor-Alpha Expression
Platinum Resistant

Interventions

DRUG: Mirvetuximab Soravtansine

Sponsor

AbbVie